An overview of antimicrobial peptides and the latest advances in their development

dc.contributor.authorSierra Ortigosa, Josep Maria
dc.contributor.authorFusté i Domínguez, Ester
dc.contributor.authorRabanal Anglada, Francesc
dc.contributor.authorVinuesa Aumedes, Teresa
dc.contributor.authorViñas, Miquel
dc.date.accessioned2020-06-03T09:21:22Z
dc.date.available2020-06-03T09:21:22Z
dc.date.issued2017-04-11
dc.date.updated2020-06-03T09:21:23Z
dc.description.abstractINTRODUCTION: The recent dramatic increase in the incidence of antimicrobial resistance has been recognized by organizations such as the United Nations and World Health Organization as well as the governments of the USA and several European countries. A relatively new weapon in the fight against severe infections caused by multi-drug resistant bacteria is antimicrobial peptides (AMPs). These include colistin, currently regarded as the last line of antimicrobial therapy against multi-drug resistant microorganisms. Areas covered: Here, the authors provide an overview of the current research on AMPs. The focus is AMPs currently being developed for the treatment of recalcitrant bacterial infections, the synergies of AMPs and antibiotics, and the activity of AMPs against biofilm. This review also includes a brief introduction into the use of AMPs in infections caused by Mycobacterium, fungi, and parasites. Expert opinion: In research into new antimicrobials, AMPs are gaining increasing attention. While many are natural and are produced by a wide variety of organisms, others are being newly designed and chemically synthesized in the laboratory to achieve novel antimicrobial agents. The same strategy to fight infections in nature is thus being effectively exploited to safeguard human and animal health.
dc.format.extent14 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec671790
dc.identifier.issn1471-2598
dc.identifier.urihttps://hdl.handle.net/2445/164122
dc.language.isoeng
dc.publisherTaylor and Francis
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1080/14712598.2017.1315402
dc.relation.ispartofExpert Opinion On Biological Therapy, 2017, vol. 17, num. 6, p. 663-676
dc.relation.urihttps://doi.org/10.1080/14712598.2017.1315402
dc.rights(c) Taylor and Francis, 2017
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (Química Inorgànica i Orgànica)
dc.subject.classificationAntibiòtics
dc.subject.classificationPèptids
dc.subject.classificationResistència als medicaments
dc.subject.classificationEspectrometria de masses
dc.subject.otherAntibiotics
dc.subject.otherPeptides
dc.subject.otherDrug resistance
dc.subject.otherMass spectrometry
dc.titleAn overview of antimicrobial peptides and the latest advances in their development
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/acceptedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
671790.pdf
Mida:
682.64 KB
Format:
Adobe Portable Document Format